Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. eHealth-mind the gap

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Telemedicine and e-Health Solutions for COVID-19: Patients' Perspective

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Electronic symptom monitoring in patients with metastatic lung cancer: a feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • A Horwich
  • M Babjuk
  • J Bellmunt
  • H M Bruins
  • T M De Reijke
  • M De Santis
  • S Gillessen
  • N James
  • S Maclennan
  • J Palou
  • T Powles
  • M J Ribal
  • S F Shariat
  • T Van Der Kwast
  • E Xylinas
  • N Agarwal
  • T Arends
  • A Bamias
  • A Birtle
  • P C Black
  • B H Bochner
  • M Bolla
  • J L Boormans
  • A Bossi
  • A Briganti
  • I Brummelhuis
  • M Burger
  • D Castellano
  • R Cathomas
  • A Chiti
  • A Choudhury
  • E Compérat
  • S Crabb
  • S Culine
  • B De Bari
  • W De Blok
  • P J L De Visschere
  • K Decaestecker
  • K Dimitropoulos
  • J L Dominguez-Escrig
  • S Fanti
  • V Fonteyne
  • M Frydenberg
  • J J Futterer
  • G Gakis
  • B Geavlete
  • P Gontero
  • B Grubmüller
  • S Hafeez
  • D E Hansel
  • A Hartmann
  • D Hayne
  • A M Henry
  • V Hernandez
  • H Herr
  • K Herrmann
  • P Hoskin
  • J Huguet
  • B A Jereczek-Fossa
  • R Jones
  • A M Kamat
  • V Khoo
  • A E Kiltie
  • S Krege
  • S Ladoire
  • P C Lara
  • A Leliveld
  • E Linares-Espinós
  • V Løgager
  • A Lorch
  • Y Loriot
  • R Meijer
  • M Carmen Mir
  • M Moschini
  • H Mostafid
  • A-C Müller
  • C R Müller
  • J N'Dow
  • A Necchi
  • Y Neuzillet
  • J R Oddens
  • J Oldenburg
  • S Osanto
  • W J G Oyen
  • L Pacheco-Figueiredo
  • H Pappot
  • M I Patel
  • B R Pieters
  • K Plass
  • M Remzi
  • M Retz
  • J Richenberg
  • M Rink
  • F Roghmann
  • J E Rosenberg
  • M Rouprêt
  • O Rouvière
  • C Salembier
  • A Salminen
  • P Sargos
  • S Sengupta
  • A Sherif
  • R J Smeenk
  • A Smits
  • A Stenzl
  • G N Thalmann
  • B Tombal
  • B Turkbey
  • S Vahr Lauridsen
  • R Valdagni
  • A G Van Der Heijden
  • H Van Poppel
  • M D Vartolomei
  • E Veskimäe
  • A Vilaseca
  • F A Vives Rivera
  • T Wiegel
  • P Wiklund
  • A Williams
  • R Zigeuner
  • J A Witjes
Vis graf over relationer

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial.

OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management.

DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference.

SETTING: Online Delphi survey and consensus conference.

PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.

OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus).

RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease.

CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind30
Udgave nummer11
Sider (fra-til)1697-1727
Antal sider31
ISSN0923-7534
DOI
StatusUdgivet - 1 nov. 2019

Bibliografisk note

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

ID: 58931520